Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853, USA.
J Biol Chem. 2010 Nov 12;285(46):35446-54. doi: 10.1074/jbc.M110.156034. Epub 2010 Sep 8.
The stereospecific oxidative degradation of uric acid to (S)-allantoin was recently shown to proceed via three enzymatic steps. The final conversion is a decarboxylation of the unstable intermediate 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) and is catalyzed by OHCU decarboxylase. Here we present the structures of Klebsiella pneumoniae OHCU decarboxylase in unliganded form and with bound allantoin. These structures provide evidence that ligand binding organizes the active site residues for catalysis. Modeling of the substrate and intermediates provides additional support for this hypothesis. In addition we characterize the steady state kinetics of this enzyme and report the first OHCU decarboxylase inhibitor, allopurinol, a structural isomer of hypoxanthine. This molecule is a competitive inhibitor of K. pneumoniae OHCU decarboxylase with a K(i) of 30 ± 2 μM. Circular dichroism measurements confirm structural observations that this inhibitor disrupts the necessary organization of the active site. Our structural and biochemical studies also provide further insights into the mechanism of catalysis of OHCU decarboxylation.
尿酸的立体专一性氧化降解最近被证明通过三个酶促步骤进行。最后一步转化是不稳定中间体 2-氧代-4-羟基-4-羧基-5-尿基咪唑啉(OHCU)的脱羧,由 OHCU 脱羧酶催化。在这里,我们展示了未配位形式和与别嘌呤醇结合形式的肺炎克雷伯氏菌 OHCU 脱羧酶的结构。这些结构为配体结合为催化组织活性位点残基提供了证据。对底物和中间体的建模为该假设提供了额外的支持。此外,我们还对该酶的稳态动力学进行了表征,并报告了第一个 OHCU 脱羧酶抑制剂,别嘌呤醇,它是次黄嘌呤的结构异构体。该分子是肺炎克雷伯氏菌 OHCU 脱羧酶的竞争性抑制剂,K(i)为 30±2 μM。圆二色性测量证实了结构观察结果,即该抑制剂破坏了活性位点的必要组织。我们的结构和生化研究还进一步深入了解了 OHCU 脱羧催化的机制。